Healthcare / Biotech
Guardant Health
30-Second Executive Brief
Executive Assessment
Guardant Health functions as an established institution within Healthcare / Biotech, backed by 0% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 0% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare / Biotech category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 0%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 3
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Liquid biopsy and precision oncology company. Guardant Health raised full-year 2026 revenue guidance to $1.34-1.36 billion after Q2 2026 sales of $334.98 million, established a strategic collaboration with Merck for companion diagnostics, secured TRICARE coverage for its Shield colorectal cancer screening test for active-duty military members, and completed the acquisition of MetaSight Diagnostics.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Yahoo Finance — Guardant Health raises 2026 revenue guidancecompany
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Guardant Health — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Guardant Health's Timeline
A sourced, dated history of Guardant Health's key moments — founding to present.
Jan 2026 · Secures TRICARE coverage for Shield
Guardant Health's Shield colorectal cancer screening test received TRICARE coverage for active-duty service members and their families, with no copay for average-risk individuals ages 45+.
Jul 2026 · Raises FY2026 revenue guidance to $1.34-1.36B
Guardant Health reported second-quarter 2026 sales of $334.98 million and raised full-year 2026 revenue guidance to $1.34-1.36 billion, with Shield screening volume of 270,000-285,000 tests expected.